Quantifying Co-eluting Peptide Impurities via High Resolution Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chromatographic methods fail to quantitatively separate impurities from peptide products, especially those with minor structural differences, leading to co-elution issues and challenges in determining the amount of impurities present in pharmaceutical peptide compositions.
Innovation Solution
High resolution mass spectrometry, with or without prior chromatography, is used to quantify impurities that cannot be separated from the main product by chromatographic procedures, involving sample preparation with known impurity additions and regression analysis to calculate impurity amounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chromatographic procedures are used to purify and analyze peptide products, then the main product can be separated from most impurities, but impurities with minor structural differences co-elute and cannot be quantitatively determined
Solution Approach 1:
The patent replaces the mechanical separation system (chromatography) with a mass spectrometric detection system. High-resolution mass spectrometry directly measures the mass-to-charge ratio of ions, enabling differentiation of impurities based on their exact molecular mass rather than relying on chromatographic separation. This substitution allows quantitative determination of co-eluting impurities that cannot be resolved by chromatographic methods.
Solution Approach 2:
The patent changes the detection parameter from chromatographic retention time to exact mass-to-charge ratio. By using high-resolution mass spectrometry, the method detects impurities based on their precise mass differences (e.g., 0.034 Da difference between Lixisenatide and Di-Ser(33)-AVE0010), enabling differentiation and quantification of impurities that co-elute in chromatography.
2Measurement precision
If high resolution mass spectrometry is used to detect impurities, then co-eluting impurities can be quantified, but the method complexity increases compared to standard chromatographic procedures
Solution Approach 1:
The patent performs preliminary chromatographic separation to remove highly abundant impurities and concentrate the peptide of interest before mass spectrometric analysis. This preliminary action reduces the complexity of the sample matrix, allowing the mass spectrometer to focus on detecting and quantifying the specific impurities of interest without interference from major contaminants.
Solution Approach 2:
The patent uses an intermediary chromatographic step as a sample preparation stage that simplifies the subsequent mass spectrometric analysis. This intermediary separation removes interfering substances and concentrates the analyte, making the complex mass spectrometric measurement more manageable and interpretable.
3Adaptability or versatility
If peptide products are produced by solid phase synthesis, then flexible production is achieved, but synthesis by-products increase to 50-70% of crude product
Solution Approach 1:
The patent replaces traditional chromatographic purification and analysis with mass spectrometric detection. This substitution enables direct quantification of synthesis by-products in the crude product without requiring extensive chromatographic separation, thereby reducing the 50-70% by-product burden while maintaining solid phase synthesis flexibility.
Solution Approach 2:
The patent changes the analytical parameter from chromatographic separation to exact mass measurement. By measuring the precise mass-to-charge ratio of synthesis by-products, the method can identify and quantify impurities directly in the crude product, eliminating the need for multiple chromatographic purification steps and reducing overall by-product handling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for accurate determination of impurities like Di-Ser(33)-AVE0010 and Di-Ala(35)-AVE0010 in Lixisenatide, enabling quality control and batch release by providing precise quantification of impurities that co-elute with the main product, enhancing the reliability of pharmaceutical peptide products.
Implementation Method 1
high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC)
Data Source
AI summary
The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.